Gujarat Themis Biosyn Ltd (IN:GUJTHEM)
:GUJTHEM
Want to see IN:GUJTHEM full AI Analyst Report?
Top Page
Gujarat Themis Biosyn Ltd
(GUJTHEM)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹464.00
▲(7.41% Upside)
Action:N/A
Date:05/28/26
The score is primarily constrained by mixed financial quality—despite strong profitability and surging revenue, leverage increased and cash generation deteriorated with deeply negative free cash flow. Technicals are supportive with a clear uptrend, but valuation is a headwind due to a high P/E and low dividend yield.
Positive Factors
High operating and net margins
Sustained high operating and net margins indicate strong unit economics and pricing power in the API business. Durable margins provide a cushion against cyclical revenue swings, support attractive returns on capital, and help fund reinvestment even if growth moderates over the next several quarters.
Negative Factors
Rising financial leverage
Rapid increase in leverage materially raises financial risk and reduces flexibility. Higher debt amplifies earnings volatility through interest burden, limits ability to invest or weather downturns, and increases refinancing pressure if cash generation does not recover over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High operating and net margins
Sustained high operating and net margins indicate strong unit economics and pricing power in the API business. Durable margins provide a cushion against cyclical revenue swings, support attractive returns on capital, and help fund reinvestment even if growth moderates over the next several quarters.
Read all positive factors
Gujarat Themis Biosyn Ltd (GUJTHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹47.24B
Dividend Yield0.16%
Average Volume (3M)8.65K
Price to Earnings (P/E)98.9
Beta (1Y)2.05
Revenue Growth9.96%
EPS Growth-4.28%
CountryIN
Employees221
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.41
Shares Outstanding108,965,260
10 Day Avg. Volume8,769
30 Day Avg. Volume8,646
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Gujarat Themis Biosyn Ltd Business Overview & Revenue Model
Company Description
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tubercul...
How the Company Makes Money
Gujarat Themis Biosyn Ltd primarily makes money by manufacturing and selling APIs and pharmaceutical intermediates to other pharmaceutical companies (business-to-business), where revenue is recognized from product sales/contracts for these materia...
Gujarat Themis Biosyn Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
64
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 800.74M | 1.66B | 1.51B |
| Gross Profit | 642.88M | 769.25M | 1.19B |
| EBITDA | 390.15M | 755.30M | 714.23M |
| Net Income | 262.62M | 466.81M | 487.72M |
Balance Sheet | |||
| Total Assets | 3.77B | 5.03B | 3.01B |
| Cash, Cash Equivalents and Short-Term Investments | 103.83M | 60.88M | 116.94M |
| Total Debt | 714.92M | 1.62B | 304.70M |
| Total Liabilities | 1.12B | 2.16B | 529.31M |
| Stockholders Equity | 2.64B | 2.88B | 2.48B |
Cash Flow | |||
| Free Cash Flow | -600.86M | -1.28B | -251.22M |
| Operating Cash Flow | 710.39M | 447.42M | 910.29M |
| Investing Cash Flow | -1.30B | -1.73B | -1.12B |
| Financing Cash Flow | 567.21M | 1.21B | 260.14M |
Gujarat Themis Biosyn Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹37.05B | 32.15 | ― | 0.85% | 8.28% | -37.15% | |
64 Neutral | ₹47.24B | 98.92 | ― | 0.16% | 9.96% | -4.28% | |
58 Neutral | ₹31.00B | 31.70 | ― | ― | 8.13% | 2910.16% | |
57 Neutral | ₹32.64B | 64.76 | ― | 0.03% | 9.88% | -40.57% | |
57 Neutral | ₹38.63B | 190.57 | ― | ― | -12.00% | -79.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ₹34.01B | -52.14 | ― | 0.06% | 83.86% | -14.25% |
* Healthcare Sector Average
IN:GUJTHEM
Gujarat Themis Biosyn Ltd
404.10
96.67
31.44%
IN:DCAL
Dishman Carbogen Amcis Ltd.
194.65
-71.40
-26.84%
IN:GUFICBIO
Gufic Biosciences Limited
334.90
-55.84
-14.29%
IN:ORCHPHARMA
Orchid Pharma Limited
790.60
159.80
25.33%
IN:RPGLIFE
RPG Life Sciences Limited
2,207.95
45.92
2.12%
IN:ZOTA
Zota Health Care Ltd.
1,125.20
126.44
12.66%
Gujarat Themis Biosyn Ltd Corporate Events
Gujarat Themis Biosyn to Buy Sanofi Anti-Infective Brands in €158 Million Deal
Apr 23, 2026
Gujarat Themis Biosyn Ltd has signed an asset purchase agreement with French drugmaker Sanofi to acquire a portfolio of 13 established anti-tuberculosis and anti-infective branded generics, along with associated trademarks, marketing authorization...
Gujarat Themis Biosyn to Buy Sanofi’s Global Anti-TB and Anti-Infective Brands
Apr 23, 2026
Gujarat Themis Biosyn Ltd has signed an asset purchase agreement to acquire Sanofi’s global portfolio of 13 anti-tuberculosis and anti-infective branded generics. The deal, subject to antitrust and foreign direct investment approvals, covers...
Gujarat Themis Biosyn Unveils Investor Presentation on Sanofi Anti-TB Asset Purchase
Apr 23, 2026
Gujarat Themis Biosyn Ltd has released an investor presentation detailing its planned asset purchase of Sanofi’s global anti-tuberculosis and anti-infective portfolio. The disclosure, made under SEBI’s listing regulations and shared wi...
Gujarat Themis Biosyn Shareholders Back Re-Appointment of Independent Director via Postal Ballot
Apr 20, 2026
Gujarat Themis Biosyn has disclosed the results of a postal ballot conducted via remote e-voting for a special resolution dated 18 March 2026. Shareholders approved the re-appointment of Mrs. Kirandeep Madan as a Non-Executive Woman Independent Di...
Gujarat Themis Biosyn Publishes SEBI-Mandated Notice on Physical Share Demat Window
Apr 8, 2026
Gujarat Themis Biosyn Ltd has announced that it has published a shareholder notice in the English and Gujarati editions of the Western Times, in line with a recent SEBI circular issued on January 30, 2026. The notice concerns a special window allo...
Gujarat Themis Biosyn Closes Trading Window Ahead of Q4 Results
Mar 24, 2026
Gujarat Themis Biosyn Ltd has announced the closure of its trading window for company shares starting 1 April 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and its internal code of conduct. The window will remain shut ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.